Does Ravulizumab Interact with Crovalimab?
CDI records a major classification for Ravulizumab and Crovalimab. The stored summary is: Formation of dual targeting drug complexes (DTDCs) when switching between crovalimab and ravulizumab can result in Type III hypersensitivity reactions. DTDCs expected to clear in longer timeframe than eculizumab. The mechanism involves crovalimab and ravulizumab bind different epitopes on c5, forming dtdcs that may trigger type iii hypersensitivity reactions. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Ravulizumab Class
- Complement Inhibitor
- Crovalimab Class
- Complement C5 Inhibitor
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Crovalimab and ravulizumab bind different epitopes on C5, forming DTDCs that may trigger Type III hypersensitivity reactions
What To Tell Your Doctor or Pharmacist
If you are taking Ravulizumab and your doctor is considering prescribing Crovalimab (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider